The US Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals Inc’s (NYSE:VRX) Siliq to treat adults with moderate-to-severe plaque psoriasis.
Plaque psoriasis – the most common form of the autoimmune disorder psoriasis – causes sufferers to develop thick, red skin with flaky, white scales.
In the clinical trials, patients treated with Siliq had shown suicidal behaviour, the FDA said.
The approval for the injection includes a labelling with boxed warning to mitigate the risks of suicide.
Shares were down 3%, or US$0.53, to US$16.28.
Story by ProactiveInvestors